Free Trial
NASDAQ:HURA

TuHURA Biosciences (HURA) Stock Price, News & Analysis

TuHURA Biosciences logo
$3.95 +0.15 (+4.03%)
Closing price 03:59 PM Eastern
Extended Trading
$3.84 -0.12 (-2.99%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About TuHURA Biosciences Stock (NASDAQ:HURA)

Key Stats

Today's Range
$3.70
$4.05
50-Day Range
$1.88
$4.23
52-Week Range
$1.80
$7.93
Volume
149,967 shs
Average Volume
254,085 shs
Market Capitalization
$172.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67
Consensus Rating
Buy

Company Overview

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Receive HURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TuHURA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HURA Stock News Headlines

TuHURA Biosciences, Inc. (HURA)
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Revolution we predicted has arrived." In fact, I believe these robots could impact 65 million Americans lives — by August of this year.
See More Headlines

HURA Stock Analysis - Frequently Asked Questions

TuHURA Biosciences' stock was trading at $4.09 at the beginning of 2025. Since then, HURA shares have decreased by 3.3% and is now trading at $3.9530.
View the best growth stocks for 2025 here
.

Top institutional shareholders of TuHURA Biosciences include Apollon Wealth Management LLC (0.26%), Suncoast Equity Management (0.23%), Sabal Trust CO (0.09%) and Hurlow Wealth Management Group Inc. (0.07%).

Shares of HURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
5/08/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HURA
Previous Symbol
NASDAQ:HURA
Web
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.67
High Stock Price Target
$15.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+231.6%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($4.11) per share
Price / Book
-0.93

Miscellaneous

Free Float
42,200,000
Market Cap
$166.86 million
Optionable
N/A
Beta
0.53
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:HURA) was last updated on 5/8/2025 by MarketBeat.com Staff
From Our Partners